Recombinant virus containing BPI gene and pharmaceutical composition containing same and uses

Abstract

The invention relates to a recombinant virus, which comprises viral vector and genes construct selected from: (1) human BPI gene or its functional fragment gene, or its degenerate sequence, (2) chimeric gene containing human BPI gene or its functional fragment gene, or its degenerate sequence, wherein the 3' end of the human BPI gene or its functional fragment gene is further connected to human immunoglobulin heavy chain constant region Fc gene or its equivalent gene. The invention also relates to the use of the gene construct containing human BPI gene or its functional fragment gene for preparing pharmaceutical composition for the gene therapy of mammal GNB and / or GNB-like pathogen infectious diseases. The invention also relates to the method for treating GNB and / or GNB-like pathogen infectious diseases by utilizing the recombinant virus or pharmaceutical composition.

Description

field of invention [0001] The invention relates to the field of gene therapy for diseases infected by Gram-negative bacteria (GNB) / or GNB-like pathogens in mammals. Specifically, the present invention relates to a recombinant virus comprising a viral vector and a gene construct selected from the group consisting of: 1) a human BPI gene or a functional fragment gene thereof, or a degenerate sequence thereof; and 2) a human BPI gene or Its functional fragment gene, or a chimeric gene of its degenerate sequence, wherein the 3' end of the human BPI gene or its functional fragment gene is further connected with the human immunoglobulin heavy chain constant region Fc gene or its allelic gene. The present invention also relates to the use of the gene construct containing the human BPI gene or its functional fragment gene for the preparation of a pharmaceutical composition for gene therapy of mammalian GNB and / or GNB-like pathogen infection diseases. The present invention also relate...

AI Technical Summary

Problems solved by technology

[0009] Non-viral vectors are safe, but the efficiency of gene transfer is low; with the development of new high-efficiency non-viral vector technology and materials (such as targeting vectors, nanocarriers, etc.), the application of such vectors in gene therapy will become more and more More and more [Manfred, et al. DDT, 7(8): 479 (2002)] [Molas, et al. Curr Gene Ther. 3: 468 (2003)]

[0010] Since Dr. Anderson, an American scientist, conducted the first clinical trial of human gene therapy in 1990, according to the statistics of the American Society of Gene Therapy (ASGT), as of March 2004, there have been 619 clinical trials of gene therapy. , involving the prevention and treatment of malignant tumors, genetic diseases, cardiovascular diseases, autoimmune diseases, neuroendocrine system diseases and AIDS, but there is no report on gene therapy for bacterial infection diseases [http: / / www.asgt.org]

Images